A detailed history of Northern Trust Corp transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 214,353 shares of TYRA stock, worth $3.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
214,353
Previous 155,451 37.89%
Holding current value
$3.3 Million
Previous $2.49 Million 102.78%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$16.7 - $24.36 $983,663 - $1.43 Million
58,902 Added 37.89%
214,353 $5.04 Million
Q2 2024

Aug 14, 2024

SELL
$14.45 - $20.22 $14,753 - $20,644
-1,021 Reduced 0.65%
155,451 $2.49 Million
Q1 2024

May 14, 2024

BUY
$11.61 - $20.0 $49,017 - $84,440
4,222 Added 2.77%
156,472 $2.57 Million
Q4 2023

Feb 13, 2024

BUY
$11.01 - $14.95 $117,267 - $159,232
10,651 Added 7.52%
152,250 $2.11 Million
Q3 2023

Nov 13, 2023

BUY
$13.15 - $16.08 $18,817 - $23,010
1,431 Added 1.02%
141,599 $1.95 Million
Q2 2023

Aug 11, 2023

BUY
$11.99 - $17.51 $391,185 - $571,281
32,626 Added 30.34%
140,168 $2.39 Million
Q1 2023

May 15, 2023

BUY
$6.85 - $16.22 $12,158 - $28,790
1,775 Added 1.68%
107,542 $1.73 Million
Q4 2022

Feb 13, 2023

BUY
$5.68 - $8.81 $11,127 - $17,258
1,959 Added 1.89%
105,767 $803,000
Q3 2022

Nov 14, 2022

BUY
$6.61 - $12.42 $4,455 - $8,371
674 Added 0.65%
103,808 $912,000
Q2 2022

Aug 12, 2022

BUY
$5.26 - $11.19 $15,937 - $33,905
3,030 Added 3.03%
103,134 $738,000
Q1 2022

May 13, 2022

SELL
$10.03 - $14.09 $33,991 - $47,751
-3,389 Reduced 3.27%
100,104 $1.07 Million
Q4 2021

Feb 08, 2022

BUY
$12.23 - $31.35 $1.27 Million - $3.24 Million
103,493 New
103,493 $1.46 Million

Others Institutions Holding TYRA

About Tyra Biosciences, Inc.


  • Ticker TYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,973,600
  • Market Cap $646M
  • Description
  • Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...
More about TYRA
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.